摘要
目的:探讨趋化因子白介素16(IL-16)与肺表面活性蛋白(SP-D)在持续性慢性鼻炎发病中的表达情况以及其作用机制。方法:30例单纯鼻中隔偏曲患者作为对照组,30例鼻中隔偏曲伴持续性慢性鼻炎患者作为研究组,应用免疫组织化学方法(SP法)检测两组鼻粘膜组织中SP-D和IL-16阳性表达情况,并探讨分析SP-D、IL-16在持续性慢性鼻炎发病中的作用及意义。结果:研究组鼻粘膜组织中的SP-D、IL-16阳性表达均显著高于对照组(P<0.05)。经Person相关性分析发现,研究组患者中血清SP-D、IL-16水平呈正相关(r=0.715,P<0.05)。结论:趋化因子IL-16与SP-D在持续性慢性鼻炎组织中呈高表达,SP-D与IL-16可能是通过动员并聚集大量促炎因子使机体维持非可控的炎症环境,故其在持续性慢性鼻炎发病机制中可能发挥了重要的作用。
Objective: To investigate the expression and mechanism of chemokines interleukin 16 (IL-16) and surfactant protein D (SP-D) in the pathogenesis of persistent chronic rhinitis. Methods: 30 patients with simple deviation of nasal septum were selected as control group,and another 30 patients with deviation of nasal septum and persistent chronic rhinitis were selected as study group, using immunohistochemical method (SP) method in the detection of two groups of nasal mucosa tissue SP-D and IL-16 positive expression,and discusses the analysis of SP-D and IL-16 in persistent chronic rhinitis the role and significance of developing the disease. Results: The positive expression of SP-D and IL-16 in nasal mucosal tissue of the study group was significantly higher than that of the control group ( P < 0.05).The person correlation analysis showed that there was a positive correlation between serum SP-D and IL-16 levels in the study group ( r=0.715,P <0.05). Conclusion: Chemokines IL-16 and SP-D are highly expressed in the tissues of persistent chronic rhinitis.SP-D and IL-16 may mobilize and aggregate a large number of pro-inflammatory factors to maintain an uncontrolled inflammatory environment,so they may play an important role in the pathogenesis of persistent chronic rhinitis.
作者
马鹏
冯俊
彭涛
MA Peng;FENG Jun;PENG Tao(Department of Otorhinolaryngology-Head and Neck Surgery,Nanchong Central Hospital,the Second Clinical Medical College of North Sichuan Medical College,Nanchong 637000,Sichuan,China)
出处
《川北医学院学报》
CAS
2019年第4期321-324,共4页
Journal of North Sichuan Medical College
基金
四川省科技厅重点研发项目(2018FZ0116)
四川省教育厅重点项目(18ZA0203)
川北医学院2016年校级科研发展计划项目(CBY-A-YB38)